Last Updated: November 16, 2026

Investigational Drug Information for Ulimorelin

« Back to Dashboard


What is the development status for investigational drug Ulimorelin?

Ulimorelin is an investigational drug.

There have been 7 clinical trials for Ulimorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Gastrointestinal Diseases, Digestive System Diseases, and Liver Diseases. The leading clinical trial sponsors are Norgine, Tranzyme, Inc., and Lyric Pharmaceuticals.

Recent Clinical Trials for Ulimorelin
TitleSponsorPhase
Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE TrialLyric PharmaceuticalsPhase 2
A Study to Assess Ulimorelin in Healthy SubjectsLyric PharmaceuticalsPhase 1
A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel ResectionNorginePhase 3

See all Ulimorelin clinical trials

Clinical Trial Summary for Ulimorelin

Top disease conditions for Ulimorelin
Top clinical trial sponsors for Ulimorelin

See all Ulimorelin clinical trials

Ulimorelin Development Update and Market Projection

Last updated: September 21, 2026

Ulimorelin is an investigational intravenous ghrelin-receptor agonist formerly developed for postoperative ileus and diabetic gastroparesis. Its clinical program did not advance to approval, and no FDA-approved ulimorelin product, Orange Book listing, commercial launch, or active pivotal program is evident in the public record. The base-case commercial forecast is therefore zero through 2030. A revived program would require new clinical development, financing, regulatory engagement, and likely additional patent work.

What is ulimorelin and how does it work?

Ulimorelin, also known as TZP-101, is a selective agonist of the ghrelin receptor, also called the growth hormone secretagogue receptor. It was designed for intravenous administration in acute-care settings.

The intended mechanism was to stimulate gastrointestinal motility, accelerate gastric emptying, and reduce the duration of postoperative bowel dysfunction. The principal development indications were:

Indication Intended use Development status
Postoperative ileus Short-term treatment after abdominal or bowel surgery Clinical development completed without approval
Diabetic gastroparesis Acute prokinetic treatment for delayed gastric emptying Early clinical investigation
Other gastrointestinal motility disorders Potential expansion opportunity No established clinical program

Ulimorelin was differentiated from oral prokinetic drugs by its intravenous route and potential use in hospitalized surgical patients. Its commercial positioning would have overlapped with alvimopan, the approved oral treatment for reducing postoperative gastrointestinal recovery time in selected bowel-resection patients. [1]

What is the current development status of ulimorelin?

Ulimorelin does not have an FDA approval or an active commercial development position disclosed by a major sponsor. Its principal clinical work occurred under Tranzyme Pharma and related development entities.

Early studies generated evidence of gastrointestinal activity, but later development did not establish a regulatory path. A Phase 2b postoperative-ileus study failed to provide a sufficient basis for advancing the program into a successful Phase 3 registration strategy. Public clinical-trial records identify ulimorelin studies in postoperative ileus and gastroparesis, but they do not show a completed FDA registration program or a subsequent approved product. [2]

Ulimorelin development timeline

Period Event Commercial implication
Mid-to-late 2000s Ulimorelin advanced into human studies Initial validation of the ghrelin-agonist approach
2008-2010 Early studies evaluated postoperative ileus and gastrointestinal motility Proof-of-concept activity was investigated
Early 2010s Phase 2b postoperative-ileus development produced inadequate results Probability of approval declined materially
2013-2014 Sponsor-level financial and strategic difficulties affected the program Continued investment became unlikely
Subsequent years No FDA approval, launch, or active pivotal program emerged Ulimorelin became a dormant or discontinued asset

The available record does not support describing ulimorelin as an active Phase 3 asset. It is more accurately classified as a discontinued or inactive clinical-stage candidate unless a private transaction or undisclosed restart has occurred.

What is the FDA regulatory status of ulimorelin?

Ulimorelin is not an FDA-approved drug. It does not have an established FDA label, approved dosage, National Drug Code, or postmarketing safety record.

The FDA pathway would require a new drug application supported by adequate and well-controlled clinical trials. Earlier clinical data would not, by themselves, establish approval eligibility. A future sponsor would probably need to address:

  • Confirmatory efficacy in a clearly defined surgical population.
  • Dose selection and infusion duration.
  • Cardiovascular and gastrointestinal safety.
  • Drug-drug interactions in hospitalized patients.
  • Duration of treatment and discharge criteria.
  • Comparative benefit against modern postoperative-care protocols.
  • Manufacturing comparability for the active pharmaceutical ingredient and finished injectable product.

No public FDA approval letter or FDA product label identifies ulimorelin as an approved active ingredient.

What is the Orange Book status of ulimorelin?

Ulimorelin has no identified Orange Book-listed product. As a result:

Orange Book issue Status
Approved reference listed drug None identified
Listed U.S. patents None associated with an approved product
Paragraph IV certification pathway Not applicable without an approved reference product
Generic launch timing No statutory generic pathway currently exists
Pediatric exclusivity None identified
New chemical entity exclusivity No granted U.S. exclusivity identified

A future sponsor could seek approval as a new drug, but a new approval would not automatically recreate the original commercial opportunity. Any regulatory exclusivity would depend on the new application, clinical designation, formulation, and applicable FDA rules.

What patents protect ulimorelin?

Ulimorelin was developed within a broader patent environment covering ghrelin-receptor agonists, peptide analogues, compositions, formulations, and therapeutic uses. The public clinical record does not establish a current, enforceable U.S. patent estate specific to a commercial ulimorelin product.

The critical patent questions are:

  1. Whether the original composition-of-matter claims remain unexpired.
  2. Whether ownership transferred when the original sponsor’s assets changed hands.
  3. Whether terminal disclaimers or maintenance-fee events affected enforceability.
  4. Whether injectable formulation claims remain active.
  5. Whether method-of-use claims cover postoperative ileus or gastroparesis.
  6. Whether manufacturing claims create a practical barrier to replication.

Because ulimorelin has no approved product, there is no reliable Orange Book-based patent-expiration date for generic planning. Any patent analysis would need to be performed at the family level across U.S., European, Japanese, and other national filings. ClinicalTrials.gov and FDA records do not provide a complete patent-chain analysis. [2,3]

Which formulations were likely protected?

The development profile indicates that the principal commercial formulation was an intravenous product for hospital use. Relevant claim categories could include:

  • Ulimorelin or a salt form as an active pharmaceutical ingredient.
  • Sterile injectable compositions.
  • Lyophilized or reconstituted products.
  • Intravenous dosing regimens after bowel surgery.
  • Use in patients with delayed gastrointestinal recovery.
  • Manufacturing methods for peptide or small-molecule intermediates.

A revived product would need to establish freedom to operate around both the active ingredient and injectable presentation. Formulation and manufacturing claims could be more relevant than expired composition claims if the original molecule has entered a weak or unprotected patent position.

Have companies challenged ulimorelin patents under Paragraph IV?

No meaningful Paragraph IV litigation pattern is established for ulimorelin. The reason is structural: Paragraph IV challenges apply to patents listed for an FDA-approved reference drug. Ulimorelin never reached that status.

There is also no established generic-drug litigation record comparable to products with active Orange Book listings. Potential future patent disputes would more likely involve:

  • Ownership of legacy patent families.
  • Enforcement against a revived developer.
  • Patent validity or expiration.
  • Manufacturing-process infringement.
  • Trade-secret claims relating to injectable production.
  • Regulatory exclusivity attached to a new sponsor’s later approval.

What patent litigation affects ulimorelin?

No active high-value patent litigation is publicly associated with an approved ulimorelin product. The absence of litigation does not establish that all historical patents have expired. It indicates that ulimorelin has not generated the commercial and regulatory conditions that normally produce Hatch-Waxman disputes.

The litigation risk for a future developer would be moderate to high during asset reactivation because the sponsor would need to reconstruct chain of title, assess legacy patent rights, and determine whether competing ghrelin-receptor programs create blocking or overlapping claims.

How does ulimorelin compare with competing drugs?

Product or candidate Mechanism Route Primary opportunity Development or market position
Ulimorelin Ghrelin-receptor agonist Intravenous Postoperative ileus, gastroparesis Unapproved, inactive
Alvimopan Peripheral mu-opioid-receptor antagonist Oral Postoperative ileus FDA-approved for selected bowel surgery patients
Prucalopride 5-HT4 agonist Oral Chronic constipation; motility disorders Approved in several markets
Relamorelin Ghrelin-receptor agonist Subcutaneous Diabetic gastroparesis Investigational
Tradipitant Neurokinin-1 antagonist Oral Gastroparesis and nausea Investigational
Metoclopramide Dopamine antagonist with prokinetic activity Oral, injectable, nasal Gastroparesis Established generic product

Ulimorelin’s strongest potential differentiation was its intravenous delivery in postoperative patients. Its weakness was the need to demonstrate clinically meaningful reduction in ileus duration against evolving surgical pathways, enhanced recovery protocols, early feeding, opioid-sparing analgesia, and existing pharmacologic treatment.

What is the market projection for ulimorelin?

The probability-adjusted forecast is zero under the current development status.

Forecast period Base-case revenue Reason
2025-2026 $0 No approval, launch, or active pivotal program
2027-2028 $0 Restart would require new sponsorship and clinical investment
2029-2030 $0 No visible regulatory path or commercial infrastructure

A theoretical revived-program scenario would produce a different result:

Scenario Estimated peak annual revenue Conditions
Base case $0 Program remains inactive
Re-entry case $25 million-$100 million Narrow U.S. postoperative-ileus label and hospital adoption
Successful specialty case $100 million-$300 million Positive Phase 3 data, differentiated efficacy, global licensing
Broad gastrointestinal expansion Above $300 million Approval in multiple motility indications and substantial clinical uptake

These are scenario estimates rather than an established market forecast. The value of the asset is driven less by the theoretical number of ileus patients than by the probability of clinical reactivation and the ability to show superiority or meaningful differentiation against alvimopan and modern perioperative care.

What revenue exposure exists for former sponsors?

There is no current product revenue attributable to ulimorelin. Any historical sponsor exposure is therefore an asset-value issue rather than a recurring-sales issue.

A transaction involving ulimorelin would likely be structured as a low upfront payment with milestone-based consideration. A buyer would discount the asset for:

  • Failed or inconclusive later-stage efficacy.
  • Absence of approval.
  • Unclear patent life.
  • Manufacturing restart costs.
  • Need for new clinical studies.
  • Competition from approved and investigational motility treatments.
  • Limited evidence of physician demand for an intravenous ghrelin agonist.

What generic-entry and biosimilar risks exist?

Traditional generic-entry risk is currently immaterial because no approved reference product exists. Biosimilar risk is also not relevant. Ulimorelin is a small-molecule or peptide-like investigational drug, not a marketed biologic with an established biosimilar pathway.

If a future sponsor obtains approval, generic risk would depend on the approved dosage form and surviving patents. Injectable products can have higher formulation and manufacturing barriers than simple oral tablets, but those barriers do not eliminate regulatory competition once patents and exclusivities lapse.

What licensing deals involve ulimorelin?

Ulimorelin was associated with Tranzyme Pharma’s development activities and strategic pharmaceutical relationships. The public record does not establish a current commercial license supporting active global development, manufacturing, or sales.

A new licensing transaction would need to resolve:

  • Global ownership of the clinical and patent assets.
  • Rights to historical clinical data.
  • Regulatory correspondence.
  • Manufacturing know-how.
  • Patent prosecution files.
  • Liability for prior studies.
  • Rights to related ghrelin-receptor compounds.

Without a verified active licensee, the asset should not be modeled as a partnered product.

How strong is the ulimorelin patent estate?

The patent estate is commercially weak on the available public record because there is no approved product, no Orange Book listing, no active launch, and no verified current enforcement program.

The estate could retain value if a surviving composition-of-matter patent, injectable formulation patent, or manufacturing patent has meaningful remaining term. That value cannot be inferred from the clinical name alone. A compound’s historical development status does not prove that its key patents remain enforceable.

Key Takeaways

  • Ulimorelin is an investigational intravenous ghrelin-receptor agonist, also known as TZP-101.
  • The principal targets were postoperative ileus and diabetic gastroparesis.
  • The program did not reach FDA approval and has no identified commercial product.
  • No Orange Book listing or meaningful Paragraph IV pathway exists.
  • No current revenue is attributable to ulimorelin.
  • The base-case market forecast through 2030 is zero.
  • A revived program could theoretically reach $25 million-$300 million in peak annual sales, but only after new clinical, regulatory, manufacturing, and commercial investment.
  • The main competitive reference point is alvimopan for postoperative ileus.
  • Patent value depends on a family-level review of historical filings, ownership, maintenance, and remaining term.

FAQs

Is ulimorelin approved by the FDA?

No. Ulimorelin has no FDA-approved indication, label, National Drug Code, or marketed U.S. product.

Is ulimorelin the same as relamorelin?

No. Both are associated with ghrelin-receptor agonism, but they are distinct investigational compounds with separate development histories.

Can a generic company launch ulimorelin?

Not through a conventional Abbreviated New Drug Application pathway at present because there is no approved ulimorelin reference product listed in the Orange Book.

Does ulimorelin have commercial potential in gastroparesis?

Theoretical potential exists, but the asset would require renewed clinical development. Competition includes metoclopramide, tradipitant, relamorelin, and other prokinetic approaches.

What is the most likely future for ulimorelin?

The base case is continued inactivity or asset abandonment. A restart would require a new sponsor to secure rights, verify patent protection, reproduce manufacturing capability, and generate new regulatory-grade efficacy data.

References

  1. U.S. Food and Drug Administration. (2015). Entereg (alvimopan) prescribing information. FDA.

  2. ClinicalTrials.gov. (n.d.). Studies evaluating ulimorelin in postoperative ileus and gastrointestinal motility disorders. U.S. National Library of Medicine.

  3. World Intellectual Property Organization. (n.d.). PATENTSCOPE patent database. WIPO.

  4. Tranzyme Pharma Inc. (2013). Corporate and clinical development disclosures relating to ulimorelin. Company filings and investor materials.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.